Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBRT and MRI-guided HDR Brachytherapy Boost for High-Risk Prostate Cancer
NCT04465500Phase 2Active, not recruiting
- Sponsor
- University of Virginia
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in prostate cancer (PCa), sponsored by University of Virginia. Primary endpoint: Genitourinary toxicity rate at 2 years. Started Jan 2025; status: active, not recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04465500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04465500.